Program Description
Hyperglycemia is one of the
most common and clinically significant adverse effects associated with PI3K/AKT
inhibitors used in the treatment of hormone receptor-positive (HR+),
HER2-negative breast cancer. With up to 80% of patients affected, this complication
poses a substantial barrier to optimal therapy and can lead to dose reductions,
treatment interruptions, or discontinuation. Proactive monitoring and early
intervention are essential to reducing the risk and severity of hyperglycemia
in patients receiving these therapies. This activity will equip oncology
pharmacists with the clinical insights and practical strategies needed to
recognize, prevent, and manage PI3K/AKT inhibitor-induced hyperglycemia.
Differences in agent-specific glycemic toxicity, evidence-based prophylactic
and management approaches, and interdisciplinary protocols that support
continuity of cancer care will be highlighted. Through expert-led discussion of
patient cases, participants will gain actionable strategies to minimize treatment
disruption and improve outcomes for patients with breast cancer.
Target Audience: Oncology Pharmacist
Type of Activity: Application
Release date: December
5, 2025
Expiration date: December
5, 2026
Learner
level: Foundational,
Intermediate
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Analyze patterns of hyperglycemia associated with specific PI3K/AKT pathway inhibitors to inform breast cancer treatment decisions.
- Apply proactive monitoring and intervention strategies to reduce the risk and severity of hyperglycemia in patients receiving PI3K/AKT pathway inhibitors.
- Explore supportive care strategies to proactively address hyperglycemia in patients receiving PI3K/AKT inhibitors and minimize treatment disruptions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here